BOLALARDA B-HUJAYRALI O‘TKIR LIMFOBLAST LEYKEMIYADA IMMUNOTERAPIYA BILAN BOG‘LIQ TOKSIKLIKLAR VA ULARNI BOSHQARISHNING ZAMONAVIY YONDASHUVLARI
Kalit so‘zlar:
B-hujayrali o‘tkir limfoblast leykoz (B-ALL), immunoterapiya, bolalar onkogematologiyasi, sitokin bo‘roni sindromi (CRS), ICANS, blinatumomab, CAR-T hujayraviy terapiya, toksiklik, neyrotoksiklik, davolash algoritmlari.Annotasiya
Ushbu maqolada pediatrik onkogematologiyada B-hujayrali o‘tkir limfoblast leykozni (B-ALL) davolashda qo‘llaniladigan zamonaviy immunoterapiya vositalari — blinatumomab, inotuzumab ozogamicin va CAR-T hujayraviy terapiyaning klinik samaradorligi hamda ular bilan bog‘liq o‘ziga xos nojo‘ya ta’sirlar tahlil qilinadi. Tadqiqotda immunoterapiya jarayonida kuzatiladigan sitokin bo‘roni sindromi (CRS), immun effektli hujayralar bilan bog‘liq neyrotoksiklik sindromi (ICANS) hamda gematologik bo‘lmagan toksikliklarning patogenezi va klinik namoyon bo‘lish shakllari yoritilgan. Mualliflar tomonidan ushbu asoratlarni erta tashxislash, xavf darajasini baholash (grading) hamda totsilizumab, kortikosteroidlar va boshqa yordamchi terapiya vositalarini qo‘llash orqali asoratlarni boshqarishning xalqaro standartlari va zamonaviy algoritmlari keltirib o‘tilgan. Maqola pediatrik onkologlar, gematologlar va reanimatologlar uchun immunoterapiya xavfsizligini ta’minlashda muhim qo‘llanma vazifasini o‘taydi.
Manbalar
1. Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. BiolBloodMarrowTransplant. 2019;25(4):625–638.
2. Pasquini M, Patel N, Plautz G, et al. ASTCT Consensus Grading for Toxicities after Immune Effector Cell Therapy. 2026.
3. Kubaney HR, Montgomery KE, Guidry L, et al. Blinatumomab Administration in Pediatric B-Lineage ALL: Expert Recommendations From the Children’s Oncology Group. Clin J OncolNurs. 2025;29(4):303–312. doi:10.1188/25.CJON.303-312.
4. Levine JE, Grupp SA, Pulsipher MA, et al. Pooled safety analysis of tisagenlecleucel in children and young adults with B-cell acute lymphoblastic leukemia. J ImmunotherCancer. 2021.
5. Peccatori N, Locatelli F, Ammerlaan ACJ, et al. Inotuzumabozogamicin in paediatric very high risk first B-cell acute lymphoblastic leukaemia relapse: ITCC-059 phase 2 trial. Lancet Haematol. 2026;13(7):e449–e459. doi:10.1016/S2352-3026(26)00104-3.
6. Mahadeo KM, Bajwa R, Abdel-Azim H, et al. Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement. Lancet Haematol. 2020;7(1):e61–e72.
7. Hypogammaglobulinemia in Children Receiving Targeted Immunotherapies for B Lineage Malignancies: Practical Guidance for Assessment and Management. 2025.
